Results 21 to 30 of about 27,778 (225)

A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [PDF]

, 2019
Background The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was first described in 2012 and attracted a great international attention due to multiple healthcare associated outbreaks.
Al-Ali, Anfal Y., Al-Tawfiq, Jaffar A., Momattin, Hisham   +2 more
core   +1 more source

Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism [PDF]

, 2003
Background. Tumor necrosis factor-alpha (TNF-alpha) is involved in the pathogenesis of chronic active hepatitis C. Polymorphisms in the promoter region of the TNF-alpha gene can alter the TNF-alpha expression and modify the host immune response.
Folwaczny, Christian, Glas, J., Konig, A., Martin, K., Schaefer, M., Schiemann, Uwe, Schmidt, F., Simperl, C., Torok, P.   +8 more
core   +1 more source

Treatment of Older Patients with Mantle-Cell Lymphoma [PDF]

, 2012
BACKGROUND: The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most patients have a relapse.
B. Coiffier, C. Thieblemont, C.H. Geisler, Cheson BD, E. Hoster, F. Di Raimondo, Foran JM, G. Lepeu, H. Tilly, H.C. Kluin-Nelemans, J. Walewski, J.K. Doorduijn, J.M. Zijlstra, L. Kanz, L. Sanhes, M. André, M. Hallek, M. Macro, M. Pfreundschuh, M. Szymczyk, M. Trneny, M. Unterhalt, M. Uppenkamp, M.H. Dreyling, O. Hermine, P. Feugier, P.J. Lugtenburg, R. Bouabdallah, R. Forstpointner, S. Kremers, S. Stilgenbauer, U. Vehling-Kaiser, Unterhalt M, V. Procházka, V. Ribrag, W. Hiddemann, W. Klapper, Zinzani PL   +37 more
core   +14 more sources

Daily interferon induction regimen using different manufactured interferons (alpha-2a or alpha-2b) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study Esquema de indução diário com interferon alfa 2-a ou alfa 2-b em combinação com ribavirina para tratamento da hepatite crônica C: estudo prospectivo randomizado

Arquivos de Gastroenterologia, 2006
BACKGROUD: Studies on hepatitis C virus kinetics showed that serum levels of interferon fall 48 h after drug administration, when viral load is increasing again.
Eduardo Lorens Braga, André Castro Lyra, Lourianne Nascimento, Eduardo Netto, Luciano Kalabrik, Luiz Guilherme Costa Lyra   +5 more
doaj   +1 more source

Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis

Viruses, 2022
Ropeginterferon alfa-2b is a novel mono-pegylated and extra-long-acting interferon, being developed for the treatment of myeloproliferative neoplasm (MPN) and chronic viral hepatitis.
Yi-Wen Huang, Albert Qin, Chan-Yen Tsai, Pei-Jer Chen   +3 more
doaj   +1 more source

Interferon alfa-associated retinopathy

Journal of Osteopathic Medicine, 1997
Abstract Interferon alia and its related compounds have been used for more than 10 years in the treatment of a number of conditions including viral illnesses, childhood hemangiomas, various cancers, and leukemia. The potential applications for this class of medication continue to grow. The use of interferon alia in experimental protocols
R B, Chambers, A, Downie, B, Foote, F H, Davidorf   +3 more
openaire   +2 more sources

Tratamento de hemangioma gigante com interferon alfa: relato de dois casos Treatment of giant hemangioma with interferon-alpha: report of two cases

Revista Brasileira de Hematologia e Hemoterapia, 2007
O objetivo do trabalho é descrever o uso de interferon alfa no tratamento de pacientes com hemangioma gigante. Os autores relatam e analisam dois casos de hemangioma gigante em tratamento com interferon alfa. IBS, 3 anos, em acompanhamento no Ambulatório
Ana Julia Balau, Livia C. De Nadai, Mônica S. Bressan, Josiane L. Simão   +3 more
doaj   +1 more source

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C [PDF]

, 2000
Background/Aims: Combination therapy with interferon-alpha (IFN-alpha) plus ribavirin is more efficacious than IFN-alpha monotherapy in previously untreated patients with chronic hepatitis C and patients with IFN-alpha relapse.
Berg, Thomas, Hoffmann, Robert M., Hopf, Uwe, Lafrenz, Michael, Leifeld, Ludger, Pape, Gerd R., Spengler, Ulrich, Teuber, Gerlinde, Zeuzem, Stefan   +8 more
core   +1 more source

Tratamento clínico do linfangioma com alfa-2a-interferon Treatment of lymphangioma with interferon-alpha-2a

Jornal de Pediatria, 2001
OBJETIVO: descrever os resultados obtidos com o uso do alfa-2a-interferon no tratamento de pacientes pediátricos com linfangiomas irressecáveis ou refratários a outros tratamentos.
Reynaldo J.S.P. de Souza, Luiz G. Tone
doaj   +1 more source

Erdheim Chester disease: a subtle quiddity; the first case reported from Nepal

Radiology Case Reports, 2020
Erdheim-Chester disease (ECD) is a rare entity throughout the world. This is the first case reported in Nepal. ECD is a rare aggressive, non-Langerhan's histocytosis of unknown origin with classical histological features.
Pawan Singh, MBBS, Roshani Shrestha, Narendra Kumar Yadav   +2 more
doaj   +1 more source